Close Menu

NEW YORK – Agilent Technologies reported after the close of the market on Thursday that its second quarter 2020 revenue growth was flat year over year. The firm noted that core revenues, which excludes the impact of currency and acquisitions and divestitures in the past 12 months, fell about 2 percent in Q2.

For the three months ended April 30, the firm reported revenues of $1.24 billion, the same figure reported in Q2 2019 but beating Wall Street analysts' average estimate of $1.21 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.